Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 10Vipivotide literatureEuropean journal of nuclear medicine and molecular imaging · RCT · Phase 12023

PROQURE-I: a phase I study adding concurrent [<sup>177</sup>Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer.

Concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT appears safe and well tolerated in treatment-naïve N1M0 prostate cancer patients, but clinical efficacy requires further investigation.

Read at European journal of nuclear medicine and molecular imagingAdd to compare

Where it sits

this study against the rest of the vipivotide corpus
3
Preclinical
5
Observational
0
Open-label
2
Randomised · this one
0
Reviews

Summary and findings

This phase I study evaluated the safety and tolerability of adding concurrent [177Lu]Lu-PSMA-617 to external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) in treatment-naïve N1M0 prostate cancer patients. Fourteen patients received standard EBRT and ADT along with varying doses of [177Lu]Lu-PSMA-617. No dose-limiting toxicity was observed, and the maximum tolerated dose was not reached.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
No dose-limiting toxicity observed, n=14.n=14Phase 12023

Abstract

The authors’ words, as European journal of nuclear medicine and molecular imaging supplied them

<h4>Purpose</h4>Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates. Adding [<sup>177</sup>Lu]Lu-PSMA-617 may improve tumour control and reduce reliance on long-term ADT. This phase-1 dose-escalation study explores the safety and tolerability of adding concurrent [<sup>177</sup>Lu]Lu-PSMA-617 with EBRT and ADT.<h4>Methods</h4>In the multi-centre phase-1 dose-escalation study (PROQURE-I), treatment-naïve cT1-4N1M0 PCa patients received standard locoregional EBRT (25-35 fractions) and 2-3 years ADT with concurrent [<sup>177</sup>Lu]Lu-PSMA-617 to determine its maximum tolerated dose (MTD). Dose levels included one cycle (3, 6 or 9 GBq in week 2 of EBRT) or two cycles (2 × 7.4 GBq in week 2 and 4). Grade ≥ 3 toxicity (CTCAE v5.0) was dose-limiting. Tumour and organ dosimetry was performed with SPECT/CT and planar imaging at 4, 24 and 168 h post-injection.<h4>Results</h4>Fourteen patients were included. No dose-limiting toxicity was observed and the MTD was not reached. Reported grade 1-2 toxicities were related to EBRT. Median absorbed dose to the primary tumour of 0.71 Gy/GBq (interquartile range (IQR) 0.5-2.9) at the 9 GBq; 0.91 Gy/GBq (IQR 0.6-1.0) at 7.4 GBq cycle 1; and 0.47 Gy/GBq (0.3-0.5) at cycle 2.<h4>Conclusions</h4>Concurrent [<sup>177</sup>Lu]Lu-PSMA-617 with EBRT and ADT is safe and well tolerated in treatment-naïve N1M0 PCa. Clinical efficacy should be evaluated in a subsequent phase 2 study.

Background

This study addresses the suboptimal five-year recurrence-free rates in N1M0 prostate cancer treated with locoregional EBRT and long-term ADT. Previous research indicated that adding [177Lu]Lu-PSMA-617 could potentially improve tumor control. This phase I study is significant as it explores the safety of this combination therapy.

Methods

The study was a multi-centre phase-1 dose-escalation trial involving treatment-naïve cT1-4N1M0 prostate cancer patients. A total of fourteen patients received standard locoregional EBRT (25-35 fractions) and 2-3 years of ADT, with concurrent doses of [177Lu]Lu-PSMA-617 at 3, 6, or 9 GBq in week 2 of EBRT or two cycles of 7.4 GBq.

Results

The primary endpoint showed that no dose-limiting toxicity was observed in the fourteen patients. The median absorbed dose to the primary tumor was 0.71 Gy/GBq at the 9 GBq dose level. Reported toxicities were grade 1-2 and related to EBRT, with the maximum tolerated dose not reached.

Interpretation

The findings suggest that concurrent administration of [177Lu]Lu-PSMA-617 with EBRT and ADT is safe, aligning with previous studies that have explored similar combination therapies. However, the lack of significant adverse effects does not necessarily imply clinical efficacy, which needs to be evaluated in future studies. The small sample size and absence of long-term follow-up data limit the conclusions that can be drawn.

Key findings

  • No dose-limiting toxicity observed, n=14.
  • Median absorbed dose to the primary tumour of 0.71 Gy/GBq (IQR 0.5-2.9) at 9 GBq.
  • Median absorbed dose of 0.91 Gy/GBq (IQR 0.6-1.0) at 7.4 GBq cycle 1.
  • Median absorbed dose of 0.47 Gy/GBq (IQR 0.3-0.5) at cycle 2.

Limitations

  • small sample size, n=14
  • no dose-limiting toxicity reached
  • short follow-up duration
  • lack of long-term efficacy data

Elsewhere in the Vipivotide corpus

DPlitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.Science (New York, N.Y.) · 2021DSARS-CoV-2 dependence on host pathways.Science (New York, N.Y.) · 2021DHundreds of COVID trials could provide a deluge of new drugs.Nature · 2022B[&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA radioligand therapy in younger prostate cancer patients: A matched-pair analysis between patients ≤ 65 and ≥ 70 years old.European journal of nuclear medicine and molecular imaging · 2023 · n=102 · No significant differences were observed for PFS (P=0.882) and OS (P=0.17).HumanBClinical value of per-treatment whole-body single-time-point automated dosimetry for [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer.European journal of nuclear medicine and molecular imaging · 2023 · n=59 · Bone marrow absorbed dose (BMAD) at C1 was significantly correlated with red blood cells (RBC, ρ = -0.3) and hemoglobin (ρ = -0.26) decline.HumanADosimetry Analysis of &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-I&amp;T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023 · n=45 · AD to the kidneys was 0.35 ± 0.10 Gy/GBq.Human